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Abstract 
Objective. Levels of circulating cytokines are elevated in inflammatory diseases. 
Previously, it was shown that interleukin (IL-)17A, in synergism with 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] and tumor necrosis factor α (TNFα), induces the 
release of granulocyte-macrophage colony-stimulating factor (GM-CSF) by murine 
osteoblasts in vitro. In this study, we further analyzed the effects of GM-CSF on 
osteoclast development in vitro. 
Methods. The effects of IL-17A, TNFα, and 1,25(OH)2D3 on the regulation of osteoclast 
development were investigated in cocultures of bone marrow-derived osteoclast 
progenitor cells (OPC) and mouse calvarial osteoblasts. Additionally, OPC were grown 
for 3 days in media containing macrophage colony-stimulating factor (M-CSF), GM-CSF, 
or M-CSF/GM-CSF. Subsequently, the osteoclastogenic potential and the capacity to 
dissolve amorphous CaP were assessed in each of the three populations of OPC. 
Results. IL-17A, in synergism with TNFα and 1,25(OH)2D3, inhibited the development of 
osteoclasts in the cocultures by stimulating the osteoblasts to release GM-CSF. GM-
CSF-treated OPC expressed traits characteristic of dendritic cells. Upon removal of GM-
CSF and supplementation of the culture media with M-CSF/ and RANKL, the cells lost 
their dendritic cell characteristics and differentiated into osteoclasts. OPC pretreated 
with GM-CSF and M-CSF/GM-CSF exhibited delayed development to osteoclasts and 
an extended proliferation phase. 
Conclusion. Elevated levels of GM-CSF in systemic inflammatory diseases may cause 
an expansion of the OPC pools in the bone, bone marrow, and blood. Upon homing to 
bone, this may lead to an increase in the number of osteoclasts and in bone resorption.  
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Introduction 
Rheumatoid arthritis (RA) is an inflammatory disease of the human skeleton. The 
imbalance between pro-and anti-inflammatory cytokines in affected joints leads to 
infiltration of the synovium by immune cells, cartilage damage, and loss of subchondral 
bone. These bone erosions are governed by pro-inflammatory cytokines, which shift the 
balance between osteoblastic and osteoclastic activities towards resorption (1, 2).  
Osteoclasts are multinucleated cells of haematopoietic origin and form by fusion of 
monocyte/macrophage lineage progenitor cells. Two growth factors, haematopoietic 
growth factor macrophage colony-stimulating factor (M-CSF) and receptor activator of 
nuclear factor κB ligand (RANKL), are essential and sufficient for osteoclastogenesis. 
RANKL binds to RANK on the surface of haematopoietic progenitor cells, activating a 
signal cascade through tumor necrosis factor receptor-associated factors (TRAFs) that 
leads to the downstream activation of inhibitor of NF-κB kinase (IKK), c-Jun N-terminal 
kinase (JNK), p38, extracellular signal-regulated kinase (ERK), and Src (2). Binding of 
RANKL to RANK is blocked by osteoprotegerin (OPG), a decoy receptor for RANKL. 
Physiologically, the RANKL:OPG ratio governs the biological efficacy of RANKL and its 
action on osteoclastogenesis. Besides M-CSF and RANKL, numerous cytokines, such 
as tumor necrosis factor alpha (TNFα), contribute to the modulation of osteoclast 
development. TNFα stimulates osteoclast differentiation indirectly by modulating the 
RANKL and OPG levels in stromal cells and directly by acting on osteoclast progenitor 
cells (OPC) in synergism with RANKL (3, 4). In vitro, osteoclasts differentiate from bone 
marrow cells (BMC) grown in culture media supplemented with M-CSF and RANKL, or 
in coculture of BMC or OPC and osteoblast lineage cells. Upon stimulation with 1,25-
4	
	
dihydroxyvitamin D3 [1,25(OH)2D3], RANKL is upregulated in mesenchymal cells, while 
OPG levels are attenuated (5, 6). 
In the microenvironment of the bone marrow, immune cells interact with bone cells to 
modulate their differentiation and activity. In the inflamed joints of patients with RA, 
activated T-cells secrete osteoclastogenic cytokines, including soluble RANKL, TNFα, 
interleukin (IL-)6, granulocyte-macrophage colony stimulating factor (GM-CSF), and IL-
17A (1, 7, 8). Furthermore, T-cells trigger macrophages, fibroblasts, and endothelial 
cells to release pro-inflammatory cytokines, resulting in increased levels in the synovial 
fluid (9-11). TNFα, IL-1, and IL-17A are targeted in RA therapies (11); inhibitory 
antibodies against these cytokines and combinations thereof attenuate both synovial 
inflammation and subchondral bone resorption (12, 13). 
TNFα and IL-17A are potent inducers of GM-CSF release by mesenchymal cells (14, 
15). GM-CSF is a member of the family of haematopoietic growth factors, which were 
originally identified by their capacity to induce colony formation in granulocytes and 
macrophages in vitro (16, 17). M-CSF and GM-CSF control the proliferation, 
differentiation, activation, and survival of monocyte/macrophage lineage cells (17). 
Studies on M-CSF-deficient op/op mice demonstrated this factor to control the 
development of most non-inflammatory macrophage populations and osteoclasts. M-
CSF-independent macrophages, mainly involved in inflammatory and immune 
responses, are not affected by the op/op mutation (18, 19).  
M-CSF is constitutively expressed by multiple cell types and circulates in the blood. GM-
CSF is not detectable in physiological conditions, but levels rise dramatically during 
immune response and inflammation (17). Besides its growth factor-like action in 
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granulocytic cells and macrophages, GM-CSF promotes the maturation of dendritic 
cells, in particular in inflammation (20). Neutralizing antibodies against GM-CSF have 
been successfully used in various models to treat autoimmune or inflammatory 
diseases, including collagen-induced arthritis (17, 21).     
In the present study, the roles of IL-17A and GM-CSF in osteoclast differentiation and 
activity were investigated in vitro, with a focus on the osteoclastogenic potential of GM-
CSF-treated OPC. The data demonstrate that IL-17A, in synergism with TNFα and 
1,25(OH)2D3, stimulates osteoblasts to release GM-CSF. Exposure of OPC to GM-CSF 
leads to a dendritic cell-like phenotype. Upon stimulation with M-CSF/RANKL, these 
cells differentiate into active osteoclasts that are able to dissolve a calcium phosphate 
(CaP) matrix.   
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Materials and Methods 
Animals. Wild-type (wt) C57Bl/6J mice and p55TNFR−/−/p75TNFR−/− double knockout 
mice on C57Bl/6J background (22) were bred at the Central Animal Facility of the 
University of Bern, in compliance with the Swiss guidelines for the care and use of 
experimental animals. The use of animals in this study was approved by the State 
Committee for the Control of Animal Experimentation (Bern, CH; permit numbers 
BE23/13 and BE54/16 to WH). 
Cell preparations and cultures. Primary murine osteoblasts were isolated by 
sequential collagenase digestion of calvariae from 1–2-day-old mice. Briefly, 25 
calvariae were digested for 5 × 20 min with 3 mg/ml collagenase type II (Worthington, 
NJ, USA) in Hank's balanced salt solution (Sigma-Aldrich, Buchs, CH). Fractions 
containing osteoblasts were pooled and seeded into 75-cm2 culture flasks (106 
cells/flask) for culture in medium (αMEM [Gibco/LuBio Science, Lucerne, CH] 
supplemented with 10% fetal bovine serum [FBS; Sigma-Aldrich] and 
penicillin/streptomycin at 100 U/ml and 100 µg/ml, respectively [Gibco]). After 4 days, 
the cells were aliquoted (106 cells/ml) and stored in liquid nitrogen. Before the 
experiments, the cells were expanded in culture medium for 4 days. 
BMC were obtained from femora and tibiae of 6- to 8-week-old C57Bl/6J mice. The cells 
were centrifuged at 250 ×g at 4°C for 7 min, and the pellet was resuspended in cell 
culture medium supplemented with M-CSF (30 ng/ml; Chiron, Emeryville, USA) and 
incubated (37°C, humidified atmosphere, 5% CO2) in 75-cm2 cell culture flasks (4 × 106 
cells/flask). After 24 h, the non-adherent cells (3 × 104 cells/well) were grown with 
primary osteoblasts (2 × 103 cells/well) in 48-well plates. The culture medium was 
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supplemented with 1,25(OH)2D3 (10-8 M; Sigma-Aldrich), recombinant murine TNFα (0.5 
ng/ml; Genentech, San Francisco, USA), and IL-17A (0.1, 1, 5, 10, or 50 ng/ml; 
PeproTech, London, UK). After 3 days, the medium was replaced, and multinucleated 
osteoclasts were visible after 4 to 5 days. 
Inhibitory antibodies (BD, Allschwil, CH) were used to assess the effects of TNFα and 
GM-CSF on osteoclastogenesis. Rat anti-mouse antibodies against TNFα and GM-CSF 
were added to the cultures at 1 µg/ml. Control cultures were treated with the respective 
isotype controls (rat IgG1 κ Isotype Ctrl and rat IgG2a κ Isotype Ctrl). In cultures with 
anti-TNFα, RANKL (10 ng/ml, recombinant human RANKL, PeproTech) was added to 
allow osteoclast formation. 
Osteoclast development in vitro. Non-adherent, M-CSF-dependent OPC were seeded 
into 5-cm petri dishes (2 × 106 cells/dish) and grown in αMEM/10% FBS supplemented 
with M-CSF (30 ng/ml), GM-CSF (0.1, 1, or 10 ng/ml; BD), and M-CSF/ GM-CSF. After 3 
days, the cells were detached by incubating them in 0.02% EDTA (Applichem, 
Darmstadt, Germany) in PBS (Dulbecco’s phosphate-buffered saline, pH 7.4; Sigma-
Aldrich) at 37°C for 10 min. The cells were seeded into new culture dishes at a density 
of 105 cells/ml. The medium was supplemented with M-CSF (30 ng/ml) and RANKL (20 
ng/ml).  
GM-CSF ELISA. GM-CSF release was quantitated in the supernatants of cultures 
treated with IL-17A, TNFα, and 1,25(OH)2D3 using a BD OptEIATM Mouse GM-CSF 
ELISA set (BD) per the manufacturer’s recommendations. The absorption was 
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measured at 450 nm (690 nm reference wavelength) on an Infinite 200Pro 
Spectrophotometer (Tecan Group Ltd., Männedorf, CH). 
Staining of osteoclast cultures for tartrate-resistant acid phosphatase (TRAP). To 
visualize osteoclasts, cultures were stained for the enzyme TRAP using a commercial kit 
(Sigma-Aldrich). Before TRAP staining, cultures were fixed with 4% paraformaldehyde 
(Merck, Darmstadt, Germany). TRAP-positive, multinucleated cells (≥ 3 nuclei) were 
counted as osteoclasts. TRAP activity was quantified in cell lysates. Cells were lysed in 
0.1% Triton X-100/1 M NaCl and frozen at -20°C. Fifty microliters of para-nitro-phenyl-
phosphate (Sigma-Aldrich; 4.61 mg/ml) was added to 50 µl of cell lysate in 40 mM Na-
tartrate/50 mM Na-acetate, pH 4.8, and incubated at room temperature. After 25 min, 
the reaction was stopped with 50 µl 0.2 M NaOH and absorption was measured at 405 
nm (690 nm reference wavelength), using an Infinite 200Pro Spectrophotometer. 
RNA isolation and quantitative reverse-transcription (qRT-)PCR. Quantitative PCR 
was used to assess gene expression in cultures treated with IL-17A, TNFα, and 
1,25(OH)2D3. Total RNA was isolated on day 5 of culture, using a NucleoSpin® RNA Kit 
(Macherey-Nagel, Oensingen, CH) per the manufacturer’s protocol. Total RNA was 
reverse-transcribed with M-MLV reverse transcriptase (Promega, Dübendorf, CH), using 
random primers (Promega), nucleotide mix (Roche, Basel, CH), and RNase inhibitors 
(Roche). PCR was carried out on an ABI7500 System (Applied Biosystems), using 
Assays-on-Demand (AoD; Applied Biosystems/LuBio Science) and TaqMan® Fast 
Universal PCR Master Mix (Applied Biosystems). After a denaturing period of 20 s at 
95°C, 45 amplification cycles of 3 s at 95°C and 30 s at 60°C were performed. The 
following AoD were used: osteoclast stimulatory transmembrane protein (OC-STAMP; 
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Mm00512445_m1), dentrocyte expressed seven transmembrane protein (DC-STAMP; 
Mm04209236_m1), integrin alpha X (CD11c; Mm00498698_m1), colony-stimulating 
factor 1 receptor (CSF-1R/cFMS; Mm01266652_m1), colony-stimulating factor 2 
receptor, alpha, low-affinity (Csf2rα/GM-CSF-Ra; Mm00438331_g1), nuclear factor of 
activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1; Mm00479445_m1), 
calcitonin receptor (CTR; Mm00432271_m1), adhesion G protein-coupled receptor E1 
(F4/80; Mm00802529_m1), and for normalization, β-glucuronidase (GUSB; 
Mm01197698_m1).  
Osteoclast activity assay. The activity of osteoclasts was assessed by their capacity to 
dissolve amorphous CaP. As described previously (23), sterile-filtered solutions of 0.12 
M Na2HPO4 and 0.2 M CaCl2 in 50 mM Tris/HCl, pH 7.4, were left in an atmosphere of 
5% CO2 at 37°C overnight. Then, 45[Ca]Cl2 (PerkinElmer, Schwerzenbach, CH) was 
added to a final concentration of 8000 Bq per well. Equal volumes were mixed in 50 ml 
tubes and CaP precipitated. The slurry was washed with water twice, resuspended with 
10 ml of water per 1 ml of slurry, and 200 µl of the suspension was added into the wells 
of 48-well plates. The plates were dried at room temperature for 3 days and baked at 
80°C for 3 h. Before use, the CaP layers were coated with αMEM/30% FBS overnight. 
Osteoclasts were generated in vitro from OPC as described above. Mature osteoclasts 
were resuspended in 500 µl of medium per dish and seeded into the CaP-coated wells 
(50 µl of cell suspension per well) in medium supplemented with M-CSF (30 ng/ml), 
RANKL (20 ng/ml), and HCl (15 mM). After 24 h, the supernatants were collected and 
45[Ca] was measured. The cells were lysed for measurement of total TRAP activity. 
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Magnet-activated cell sorting (MACS) and flow cytometry. GM-CSF-dependent 
progenitor cells (4 × 108) were incubated with anti-CD11c magnetic beads at 4°C for 15 
min and loaded onto columns that were placed in a magnetic cell separator (all from 
Miltenyi Biotech, Bergisch Gladbach, Germany). Positive (adherent) and negative (non-
adherent) cell fractions were collected and counted. The individual cell fractions were 
differentiated into osteoclasts in culture media supplemented with M-CSF/RANKL as 
described above. Unsorted cells with and without beads served as controls. To assess 
the efficiency of the sorting procedure, the cells were analyzed by flow cytometry. After 
washing of the cells with staining buffer (PBS, 0.02% sodium azide, 2% FCS), they were 
labeled with FITC-conjugated anti-CD11c antibody (BioLegend, San Diego, CA, USA) 
for 20 min on ice and analyzed in an LSR ΙΙ SORP (BD). Isotype-matched antibodies 
(BD) were used as negative controls and BD™ CompBeads were used for 
compensation. Data were analyzed using the FLOWJO software, version 10. 
EdU proliferation assay. To assess proliferation during osteoclast formation from OPC, 
cells were labeled with the thymidine analogue EdU (5-ethynyl-2´-deoxyuridine). The 
Click-iT® EdU Alexa Fluor® 488 Imaging Kit (Invitrogen/LuBio Science) was used, 
following the manufacturer’s protocol. OPC were cultured on cover slips, and on days 3 
and 4 of culture, 2 µM EdU was added for 4 h. Then, the medium was replaced with 
fresh culture medium supplemented with M-CSF/RANKL. Two days later, the cells were 
fixed and the EdU incorporated into the DNA was fluorescently labeled according to the 
Click-iT® protocol. Cell nuclei were stained with 5 µg/ml Hoechst 33342 (Sigma-Aldrich) 
in PBS for 30 min and osteoclasts were visualized by TRAP staining. The percentage of 
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nuclei with incorporated EdU was assessed by counting EdU-positive nuclei and total 
nuclei within osteoclasts on microphotographs of an area of 8.4 mm2 per cover slip. 
Statistical analysis. Differences in osteoclast numbers and percentages of proliferating 
nuclei were evaluated by nonparametric t-tests, using IBM SPSS Statistics version 22 
for Windows. P-values < 0.05 were considered significant.  
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Results	
IL-17A in synergism with TNFα inhibits the formation of osteoclasts in cocultures. 
To assess the effects of IL-17A, TNFα, 1,25(OH)2D3, and various combinations thereof 
on osteoclast formation in vitro, wt OPC were cocultured with osteoblasts from either wt 
mice or p55TNFR−/−/p75TNFR−/− mice. In cocultures with C57Bl/6J wt osteoblasts 
supplemented with 1,25(OH)2D3/TNFα, IL-17A inhibited osteoclastogenesis, reducing 
the number of osteoclasts by ≥90% at 1 ng/ml. In cocultures with C57Bl/6J wt 
osteoblasts in the absence of TNFα, only few osteoclasts developed, and IL-17A 
enhanced osteoclast formation by a factor of 6, reaching approx. 20% as compared to 
1,25(OH)2D3/TNFα (Suppl. Fig. 1A). In cocultures with osteoblasts from 
p55TNFR−/−/p75TNFR−/− mice, the inhibitory effect of IL-17A on osteoclast development 
was largely abolished (Suppl. Fig. 1B). 
Concomitant action of TNFα and GM-CSF is required for IL-17A-mediated 
inhibition of osteoclastogenesis. To assess the specific roles of TNFα and GM-CSF 
in the IL-17A-mediated inhibition of osteoclastogenesis in vitro, blocking antibodies 
against TNFα and GM-CSF were added to the cocultures. Since only low numbers of 
osteoclasts were formed in cocultures with osteoblasts from C57Bl/6J mice in the 
absence of TNFα, exogenous RANKL (10 ng/ml) was added together with anti-TNFα 
antibodies and with the respective controls (Fig. 1A,B). 
Blocking of TNFα, in the presence of RANKL, abrogated the inhibition of 
osteoclastogenesis by IL-17A (Fig. 1A), while in cultures with IgG control antibodies, 
osteoclast development was inhibited by 95% by IL-17A at 1 ng/ml, irrespective of the 
presence of RANKL (Fig. 1B,D). In cocultures with media supplemented with TNFα, 
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without 1,25(OH)2D3, osteoclast formation was reduced to approx. one third, but the 
inhibitory effect of IL-17A was unabated (Fig. 1B). On the other hand, IL-17A was 
ineffective in cocultures with media supplemented with 1,25(OH)2D3 alone (Fig 1A,B). 
Attenuation of the IL-17 effect was also observed upon addition of anti-GM-CSF 
antibodies to cocultures grown with TNFα and 1,25(OH)2D3 (Fig. 1C). In culture media 
without exogenous TNFα, IL-17A induced an increase in the number of osteoclasts (Fig. 
1C,D).  
Osteoblasts from C57BL/6J mice release GM-CSF upon treatment with IL-17A, 
1,25(OH)2D3, and TNFα. The release of GM-CSF by primary osteoblasts in response to 
an exposure to IL-17A was assessed in cultures grown with 1,25(OH)2D3 (10-8 M)/TNFα 
(0.5 ng/ml). GM-CSF accumulated in the culture supernatant over 72 h in a time- and 
dose-dependent manner, and the release was fully blocked by anti-TNFα antibodies 
(Suppl. Fig. 2). 
Characterization of the phenotype of monocyte/macrophage lineage cells exposed 
to M-CSF, GM-CSF, or M-CSF/GM-CSF. OPC were cultured with M-CSF (30 ng/ml), 
GM-CSF (0.1, 1, or 10 ng/ml), and various concentrations of M-CSF/GM-CSF, and 
phenotypic markers were assessed by qRT-PCR. Supplementation of the culture 
medium with GM-CSF caused a decrease in the level of mRNA encoding the pan-
macrophage marker F4/80 (Fig. 2A). Transcript levels of the dendritic cell marker CD11c 
were dose-dependently increased by exogenous GM-CSF, independently of the 
presence of M-CSF (Fig. 2B). Similar expression patterns were observed for DC-STAMP 
(Fig. 2C) and OC-STAMP (Fig. 2D). Levels of cFMS mRNA were dose-dependently 
decreased with increasing concentrations of GM-CSF (Fig. 2E). CSF2R transcripts were 
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upregulated by GM-CSF, while the presence of M-CSF prevented this increase (Fig. 
2F).  
OPC precultured with M-CSF, GM-CSF, or M-CSF/GM-CSF give rise to osteoclasts. 
OPC were cultured with M-CSF (30 ng/ml), GM-CSF (10 ng/ml), or M-CSF/GM-CSF. 
The potential of the OPC to develop into osteoclasts was assessed by subsequent 
culture with M-CSF (30 ng/ml)/RANKL (20 ng/ml). Starting on day 0 of osteoclast 
culture, cells were collected daily and total RNA was prepared for qRT-PCR. 
In M-CSF-treated OPC, F4/80 transcript levels were twofold higher than those in OPC 
treated with GM-CSF and M-CSF/GM-CSF at day 0. Thereafter, F4/80 transcript levels 
decreased before an induction at day 5 of the osteoclast culture (Fig. 3A). OPC 
pretreated with GM-CSF and M-CSF/GM-CSF were characterized by increased mRNA 
levels of CD11c (Fig. 3B), DC-STAMP (Fig. 3C), and OC-STAMP (not shown). The 
respective transcript levels decreased over time upon exposure to M-CSF/RANKL. With 
the development of osteoclasts, the levels of DC-STAMP and OC-STAMP transcripts 
rebounded, which was also observed in cultures of OPC pretreated with M-CSF. 
Expression of transcripts encoding the osteoclast transcription factor NFATc1 (Fig. 3D) 
preceded the expression of OC markers and the development of OC. CTR mRNA levels 
(Fig. 3E) increased with cell differentiation and correlated with the numbers of 
osteoclasts (Fig 3F).  
Osteoclasts generated from M-CSF, GM-CSF, and M-CSF/GM-CSF-treated OPC 
dissolve CaP in vitro. The capacity of osteoclasts generated from M-CSF, GM-CSF, 
and M-CSF/GM-CSF dependent OPC to dissolve CaP mineral was assessed by 
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seeding mature cells onto a layer of 45Ca-spiked amorphous CaP (Fig. 4A). Osteoclasts 
developed faster from M-CSF- than from GM-CSF- and M-CSF/GM-CSF-treated OPC 
(Fig. 4B). Upon transfer of mature OPC onto the CaP layers, TRAP activity was the 
same in all 3 groups in the cell suspension and after 1 h of adherence (Fig. 4C). Within 
24 h, total TRAP activity from M-CSF-dependent OPC decreased by 20%, while 
increasing by more than 50% in cultures of osteoclasts from GM-CSF- and M-CSF/GM-
CSF-dependent OPC (Fig. 4C). Cells in the latter cultures released twofold higher 
amounts of 45Ca than M-CSF-dependent OPC (Fig. 4D). Despite the increased 
dissolution of CaP, the release of 45Ca per TRAP after 24 h was similar among all 
osteoclast populations (Fig. 4D).  
CD11c+, GM-CSF-dependent OPC give rise to active osteoclasts. To check whether 
the CD11c+ dendritic-like cells or a CD11c- subpopulation of the GM-CSF-dependent 
OPC give rise to osteoclasts, CD11c+ cells were isolated by MACS (CD11cbright). 
Unsorted cells, CD11cdim, and CD11cbright cells were differentiated into osteoclasts and 
their capacity to dissolve CaP was assessed. In total GM-CSF-dependent OPC (F1) and 
in control cells with anti-CD11c magnetic beads (F2), ca. 70% of the cells were CD11c+, 
with median fluorescence intensities (MFI) of the positive cells at 10,796 and 10,110 
respectively. The negatively (flow through) sorted cells were 55% positive (CD11cdim; 
F3; MFI 6,267), and 98% of the positively (adherent) sorted cells (CD11cbright; F4; MFI 
24,978) expressed CD11c (Fig. 5A). All populations gave rise to TRAP-positive, multi-
nucleated osteoclasts (Fig. 5B), with similar trends being observed for total TRAP 
activity (Fig. 5C) and dissolution of CaP mineral (Fig. 5D).  
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Osteoclasts differentiated from GM-CSF-treated progenitors have a higher 
proliferation potential than those developed from M-CSF-treated progenitors. To 
investigate whether the difference in osteoclast development from M-CSF- and GM-
CSF-dependent OPC is correlated with cell proliferation, the cells were labeled at day 3 
or day 4 with EdU, and nuclear labeling was quantitated at days 5 and 6 of culture. 
Nuclei were visualized with Hoechst (Fig. 6A,C,E), and mitotic nuclei with EdU (Fig. 
6B,D,F). The percentage of labeled nuclei was threefold higher in osteoclasts from GM-
CSF- and M-CSF/GM-CSF-dependent OPC than in those from M-CSF-dependent OPC 
after the addition of EdU to the cultures at day 3, and twofold higher when EdU was 
added at day 4 (Fig. 6G). After six days in culture, the total number of nuclei was 
doubled in osteoclasts differentiated from OPC dependent on GM-CSF and M-CSF/GM-
CSF as compared to osteoclasts derived from M-CSF-dependent OPC (Fig. 6H).
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Discussion 
The present study shows that IL-17A in synergy with TNFα and 1,25(OH)2D3 inhibits the 
formation of osteoclasts in vitro through osteoblast-derived GM-CSF. The growth factor 
directs OPC differentiation towards a dendritic cell-like phenotype. Upon exposure to M-
CSF/RANKL, differentiation towards osteoclasts was delayed in GM-CSF-pretreated 
OPC, allowing proliferation over a longer period, resulting in the expansion of the OPC 
pools and the development of higher numbers of osteoclasts in vitro. 
The effects of IL-17A on osteoclastogenesis in vitro are indirect, targeting osteoblast 
lineage cells in cocultures. The cytokine induces an increase in RANKL and a decrease 
in OPG expression, thus supporting an osteoclastogenic microenvironment (data not 
shown). Simultaneously, IL-17A in synergy with TNFα and 1,25(OH)2D3 stimulates the 
release of GM-CSF, which is considered to act as an inflammatory cytokine (17, 24) and 
as an inhibitor of osteoclast development (14, 15, 25). This specific effect of IL-17A on 
osteoblast lineage cells contrasts the previously described dual effects of TNFα; 
inhibiting osteoclast development indirectly by inducing osteoblast lineage cells in 
synergy with 1,25(OH)2D3 to release GM-CSF (14), while stimulating osteoclastogenesis 
through a direct effect on OPC (3, 4, 26, 27). Haematopoietic growth factors act in 
sequence on haematopoietic stem cells and, depending on the factor, cells differentiate 
towards specific lineages (28, 29). GM-CSF acts on early progenitor cells and blocks 
their differentiation towards the monocyte/macrophage and osteoclast lineages (15). In 
the presence of GM-CSF, the cells fail to raise levels of RANK, consequently leading to 
interruption of RANK/RANKL signaling. Therefore, the addition of exogenous RANKL to 
cocultures could not abrogate the inhibitory effect of GM-CSF. Several studies have 
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shown that the inhibition of osteoclastogenesis by GM-CSF prevents the induction of c-
Fos and Fra-1, and indeed, overexpression of c-FOS by retroviral infection rescued 
osteoclast differentiation despite the presence of GM-CSF (14, 30). In a later 
differentiation stage, characterized by high levels of RANK, GM-CSF no longer affects 
osteoclastogenesis (15, 25).  
The second part of the study provides evidence that GM-CSF-dependent OPC express 
a dendritic cell-like phenotype, characterized by the expression of CD11c and DC-
STAMP, but not to undergo irreversible commitment to the dendritic cell lineage. Upon 
exposure to M-CSF/RANKL, CD11c and DC-STAMP transcript levels were decreased in 
GM-CSF-pretreated OPC, before they developed into osteoclasts and reassumed the 
expression of DC-STAMP.  
The effect of GM-CSF on OPC depends on its concentration. In cultures in the presence 
of GM-CSF in the picogram range, cells remained CD11c-, even though differentiation to 
osteoclasts was blocked (14). Treatment of OPC with M-CSF and GM-CSF in the 
nanogram range increased CD11c expression dose-dependently, with a concomitant 
loss of the pan-macrophage marker F4/80. The concentration-dependent action of GM-
CSF on haematopoietic cells may be caused by differential activation of signaling 
pathways, analogous to the action of transforming growth factor β (TGFβ) on 
haematopoietic cells (31). 
DC-STAMP is required for the regulation of dendritic cell activity and the maintenance of 
immune self-tolerance (32, 33), but it is also present on late OPC and, together with OC-
STAMP, participates in cell fusion (34, 35). In OPC, levels of DC-STAMP and OC-
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STAMP transcripts increased in parallel with those of CD11c. In cultures of GM-CSF-
pretreated OPC, DC-STAMP and OC-STAMP mRNA levels decreased and then 
increased again with osteoclast maturation. This loss of DC-STAMP and OC-STAMP 
expression during osteoclast culture indicates that GM-CSF pretreated progenitors first 
lose their dendritic cell-like phenotype before fusing into multinucleated osteoclasts. 
Based on the expression of osteoclast transcription factor NFATc1 and on the time 
course of the detection of osteoclasts in culture, osteoclasts from GM-CSF-pretreated 
OPC do not differ from osteoclasts generated from M-CSF-pretreated OPC, while their 
differentiation is delayed. This contrasts a recent report postulating that dendritic cells 
directly fuse to form osteoclasts, so-called DC-OC (36). However, no specific markers 
for DC-OC, which would allow distinguishing them from “normal” osteoclasts, are 
available at present. It has been shown that immature dendritic cells generated from 
human blood monocytes differentiate into functional osteoclasts in the presence of M-
CSF and RANKL (37). Furthermore, conventional dendritic cells were found to resolve 
the osteopetrotic phenotype within one month when injected into osteopetrotic oc/oc 
mice defective in osteoclast resorption (38). The differentiation mechanisms, however, 
were not elucidated in these studies, and taking into account the time frame before 
effects were observed, it is likely that these cells underwent dedifferentiation before 
developing into osteoclasts. 
Osteoclasts from GM-CSF-treated OPC showed the same capacity to dissolve mineral 
as osteoclasts from M-CSF-treated OPC, but are delayed in differentiation. After transfer 
onto CaP at day 5, TRAP activity further increased, which was in contrast to osteoclasts 
from M-CSF-pretreated OPC, whose number and TRAP activity decreased 
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simultaneously. Thus, osteoclasts from GM-CSF-pretreated progenitors had more time 
to proliferate in the coculture and to leave the cell cycle at a later time point than did M-
CSF-pretreated OPC, resulting in a higher number of late progenitors capable of 
differentiation and fusion. These findings are in accordance with studies demonstrating 
the proliferative effects of GM-CSF on haematopoietic progenitor cells (39-41).  
The present study provides evidence for the action of GM-CSF as a positive modulator 
of osteoclastic activity in the context of inflammatory disease, despite its direct inhibitory 
effect in vitro on osteoclastogenesis. Furthermore, it confirmed that cells expressing the 
dendritic cell marker CD11c are not irreversibly committed to the dendritic cell lineage, 
but can give rise to osteoclasts upon stimulation with M-CSF/RANKL (25, 37, 38). 
Osteoclasts and dendritic cells derive from the same myeloid progenitors, and 
differentiation has been shown to be regulated by M-CSF and GM-CSF (30). However, 
as described above, the action of GM-CSF depends on the timing and the differentiation 
state of the cells, and GM-CSF overrides M-CSF signaling in early haematopoietic 
progenitors (39). Besides its systemic effects, GM-CSF secreted by activated T-cells in 
inflamed joints may also locally increase the number of dendritic cells, which may serve 
as precursors of osteoclasts and contribute to the exacerbated osteoclastogenesis in RA 
(42-44). 
It has been postulated previously that OPC and osteoclasts may develop and mature in 
different physical compartments in the organism (14). In circulation, elevated levels of 
GM-CSF, as they occur in inflammatory diseases, act by increasing the proliferation of 
haematopoietic progenitor cells (45). It was reported that the pool of CD11c+ cells is 
expanded in RA patients (46, 47). Upon recruitment to the bone, the composition of the 
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haematopoietic microenvironment changes; RANKL from activated T-cells and 
osteoblasts takes over and locally induces the development of osteoclasts (7).  
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Figure Legends  
Figure 1. Effects of IL-17A, TNFα, and 1,25(OH)2D3 on the development of osteoclasts 
in cocultures of wt osteoblasts and OPC. Cells were cultured with or without IL-17A, 
TNFα, and 1,25(OH)2D3 and stained for TRAP after 5 days. Addition of IL-17A to 
cocultures with TNFα and 1,25(OH)2D3 resulted in a dose-dependent inhibition of 
osteoclast formation. Neutralizing antibodies against TNFα and GM-CSF attenuated the 
inhibitory effect of IL-17A. A, anti-TNFα/RANKL; B, IgG1 κ Isotype control/RANKL; C, 
anti-GM-CSF; D, IgG2a κ Isotype control. Bars show the mean ± SD (n = 6). 
Figure 2. Effects of M-CSF, GM-CSF, and M-CSF/GM-CSF on gene expression by 
OPC. Levels of transcripts coding for F4/80 (A), CD11c (B), DC-STAMP (C), OC-
STAMP (D), cFMS (E), and CSF2R (F) were quantitated by qRT-PCR and normalized to 
levels of transcripts encoding GUSB. GM-CSF dose-dependently upregulated CD11c, a 
marker for dendritic cells, and downregulated the pan-macrophage marker F4/80. DC-
STAMP and OC-STAMP mRNA levels were elevated with increasing doses of GM-CSF. 
Bars show the mean ± SD (n = 3). 
Figure 3. OPC, pretreated with M-CSF, GM-CSF, or M-CSF/GM-CSF, give rise to 
osteoclasts. OPC were cultured with M-CSF (30 ng/ml; white bars), GM-CSF (10 ng/ml; 
grey bars), or M-CSF/GM-CSF (black bars) for 3 days. The osteoclastogenic potential of 
the three OPC populations was assessed by culturing the cells in media supplemented 
with M-CSF/RANKL. Levels of transcripts encoding F4/80 (A), CD11c (B), DC-STAMP 
(C), NFATc1 (D), and CTR (E) were quantitated and osteoclasts were counted (F). GM-
CSF, alone or in combination with M-CSF, caused an increase in CD11c and DC-
STAMP transcripts. The levels of CD11c and DC-STAMP mRNA decreased gradually 
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after starting M-CSF/RANKL treatment, while DC-STAMP mRNA levels increased again 
in parallel to osteoclast development, as was observed in M-CSF treated OPC. 
Osteoclast formation was delayed in cultures of GM-CSF- and M-CSF/GM-CSF-treated 
OPC. (A) – (E): bars show the mean ± SD (n=3); (F): bars show the mean ± SD (n = 6). 
Figure 4. Osteoclasts generated from OPC pretreated with M-CSF, GM-CSF, and M-
CSF/GM-CSF dissolve amorphous CaP. A, Osteoclasts on the mineral were stained for 
TRAP followed by phase-contrast imaging. The resorbed surfaces are visible as bright 
areas. Scale bar = 100 µm. B, Osteoclastogenesis from the OPC populations was 
followed over time. C, Total TRAP activity was measured after 0 h (before seeding onto 
CaP), after 1 h (adhesion), and after 24 h. D, Release of 45Ca after 24 h was normalized 
to total TRAP activity. Bars show the mean ± SD (n = 6). 
Figure 5. CD11c-positive cells give rise to osteoclasts. OPC were treated for 3 days with 
GM-CSF, and CD11c+ cells were sorted by MACS. The potential of the cell fractions 
(non-sorted, CD11cbright, CD11cdim) to develop into osteoclasts was assessed by 
culturing the cells in media supplemented with M-CSF/RANKL. After sorting, the cells 
were analyzed by flow cytometry. A, The CD11cbright were nearly 100% positive for 
CD11c. After 5 days, the cells were stained for TRAP. B, All fractions gave rise to 
osteoclasts. C, Osteoclast development over time was similar for all 4 OPC populations 
as assessed by total TRAP activity in the cultures (days 3, 4, 5, 6 from white bars to 
black bars). D, Release of 45Ca, normalized to TRAP activity after 1 h (white bars), 12 h 
(grey bars), and 24 h (black bars). Osteoclasts from all OPC populations were able to 
dissolve CaP. F1: OPC, F2: unsorted cells, incubated with magnetic beads, F3: 
CD11cdim, F4: CD11cbright. Bars show the mean ± SD (n = 6). 
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Figure 6. Proliferation of OPC pretreated with M-CSF, GM-CSF, and M-CSF/GM-CSF 
during osteoclastogenesis. OPC were precultured with M-CSF (white bars), GM-CSF 
(grey bars), and M-CSF/GM-CSF (black bars) and subsequently grown in media 
supplemented with M-CSF/RANKL. On days 3 and 4, the cultures were labeled with 
EdU for 4 h. Two days later, the cultures were stained with Hoechst dye and for EdU. 
Arrows indicate Hoechst-positive nuclei within osteoclasts, positive or negative for EdU. 
Scale bar = 100 µm. A, M-CSF-pretreated OPC, Hoechst staining and phase contrast; 
B, M-CSF-pretreated OPC, EdU staining and phase contrast; C, GM-CSF-pretreated 
OPC, Hoechst staining and phase contrast; D, GM-CSF-pretreated OPC, EdU staining 
and phase contrast; E, M-CSF/GM-CSF-pretreated OPC, Hoechst staining and phase 
contrast; F, M-CSF/GM-CSF-pretreated OPC, EdU staining and phase contrast; G, 
Proportion of EdU-positive to total nuclei; H, Total number of nuclei within osteoclasts. 
Six pictures per well were evaluated, corresponding to an area of 8.4 mm2. Bars show 
the mean ± SD of triplicate cultures. ***P≤ 0.05, **P≤ 0.01, *P≤ 0.001 versus M-CSF-
treated OPC culture. 
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Supplementary figures 
Suppl. Figure 1. TNFα  is required for IL-17A mediated inhibiton of osteoclast 
formation. A, Effects of IL-17A, TNFα, and 1,25(OH)2D3 on the development of OC in 
cocultures of wt OB and OPC. The addition of IL-17A to cultures supplemented with 
TNFα and 1,25(OH)2D3 resulted in a dose-dependent inhibition of OC formation. In the 
absence of TNFα, 1,25(OH)2D3-mediated	OC formation was stimulated by IL-17A. In the 
absence of 1,25(OH)2D3, no OC did form. B, Effect of IL-17A on the development of OC 
in cocultures of p55TNFR−/−/p75TNFR−/− OB and wt OPC. The inhibitory effect of IL-17A 
in the presence of TNFα and 1,25(OH)2D3 was abolished. Cultures were stained for 
TRAP on day 5 and osteoclasts were counted. Bars show the mean ± SD (n = 6).	
   
Suppl. Figure 2. Osteoblasts release GM-CSF upon stimulation with IL-17A, TNFα, and 
1,25(OH)2D3. GM-CSF protein levels in the culture supernatants were quantified by 
ELISA. Wt OB were cultured with different concentrations of IL-17A in the presence of 
TNFα and 1,25(OH)2D3 for 2, 4, 8, 24, and 72 h. IL-17A dose-dependently increases the 
levels of GM-CSF released into the medium. Addition of anti-TNFα (1 ng/ml) prevented 
GM-CSF release. Bars show the mean ± SD of triplicate cultures. Ab = anti-TNFα 
antibodies. 
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